Icatibant

Drug #2274

Icatibant is a Selective Competitive Antagonist at bradykinin type 2 receptor. it is a synthetic decapeptide with structure similar to bradykinin , but with 5-non-proteinogenic Amino Acids.it is mainly indicated for symptomatic treatment of acute attacks of hereditary Angioedema in adult with C- Esterase Inhibitor deficiency.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Decapeptide.

It belongs to Bradykinin type II receptor Antagonist pharmacological group on the basis of mechanism of action.

Non-proprietary name: Icatibant.

Pharmacokinetics

Absorption: Icatibant has an oral bioavailability is 48.5% (±48.5%).

Distribution: Icatibant has a volume of distribution is 20-25L. plasma protein binding is 44%.

Elimination: it is metabolised via Hepatic, plasma half-life is 1-2 hours.

Indications

Icatibant is primarily indicated in conditions like Hereditary angioedema.

Contraindications

Icatibant is contraindicated in conditions like Hypersensitivity to the drug.

Dosage

Icatibant's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
30 mg	30 mg	Every 24h	SC	Icatibant is injected Slowly due to volume to be administered is 3ml. if insufficiency , 2nd injection after 6hours, if needed, again after 6 hours, but not more than 3 in a period of 24hours.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

The signs and symptoms that are produced after acute overdosage of Icatibant are Hypotension, Erythema, itching.

Icatibant is known to cause more or less tolerable side effects which are usually transient. These include Abnormal LFT, Asthenia , Asthma, contusion, Cough , Dizziness, Erythema, Fatigue, Headache, hereditary angioedema, herpes zoster, Hot flushes, increase blood creatinine phosphokinase, increase Blood glucose, Injection site reactions, Nasal congestion , Nausea and vomiting, Pharyngitis, prolong prothrombin time, Proteinuria , Pruritus , Pyrexia , Rashes , Urticaria.

Warnings / Precautions

Caution should be made while administering icatibant to patient with ischemic heart disease, stroke. First treatment should be given in a medical institution under guidance of physician. patients experiencing laryngeal attack should be observed after adminstration of icatibant at home. patients should be advised to not drive when feeling tired or dizzy

Available Brands

None recorded.

Storage Conditions

Icatibant should be stored .

Drug Classification

1.3 — Anti-allergics (Antihistamines) and drugs used in anaphylaxis